stockrow
Saturday 7 November 2026
Export ARTL’s income statement to Excel — free account
Artelo Biosciences, Inc.
ARTL Healthcare Biotechnology
- EPS
- +94.7%
- Free cash flow
- −879.2%
Quarter to June 2026, against a year earlier
1.96
0.16
−7.55%
Follow ARTL
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | — | — | 133 | 133 | 133 | 0.0% | |
| Gross margin, % | — | — | 0.00 | 0.00 | 0.00 | — | — | — | — | — | 0.00 | 0.0 pt | ||||||
| EBT | 0 | 0 | (2) | (2) | (5) | (7) | (10) | (9) | (10) | (13) | (13) | +56.0% | ||||||
| EBT margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | 0 | 0 | (2) | (2) | (5) | (7) | (10) | (9) | (10) | (13) | (13) | n/m | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | (9.44) | (65.33) | (4,455.36) | (2,428.46) | (3,049.37) | (967.71) | (576.72) | (508.68) | (494.10) | (338.11) | (202.60) | +48.8% | ||||||
| Cash flow | 0.00 | (60.22) | (3,220.00) | (3,103.00) | (2,898.00) | (797.53) | (457.60) | (448.47) | (419.60) | (223.62) | (41.93) | n/m | ||||||
| Capex | 0.00 | 0.00 | (1.60) | (1,667.44) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (1.63) | 0.00 | n/m | ||||||
| Free cash flow | 0.00 | (60.22) | (3,221.60) | (4,770.44) | (2,898.00) | (797.53) | (457.60) | (448.47) | (419.60) | (225.25) | (41.93) | n/m | ||||||
| Book value | (4.45) | 151.33 | (270.00) | 6,068.00 | 2,583.33 | 1,563.90 | 1,108.74 | 642.19 | 143.57 | (33.39) | 16.58 | +25.1% | ||||||
| Shares, m | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | +32.1% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | 0 | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | 0 | 0 | (2) | (3) | (4) | (6) | (8) | (8) | (8) | (9) | (13) | +142.8% | |||||
| Capex | 0 | — | 0 | (2) | — | — | — | — | — | 0 | 0 | n/m | ||||||
| Free cash flow | 0 | 0 | (2) | (4) | (4) | (6) | (8) | (8) | (8) | (9) | (13) | +143.0% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | 0 | 1 | 0 | 3 | 2 | 10 | 17 | 10 | 1 | (3) | 3 | +84.1% | |||||
| Net debt | 0 | (1) | 0 | (4) | (2) | (10) | (16) | (10) | (2) | (1) | (4) | +76.6% | ||||||
| Shareholders’ equity | 0 | 1 | 0 | 5 | 4 | 12 | 19 | 12 | 3 | (1) | 5 | +65.3% | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | (13,050.00) | (81.80) | (482.55) | (63.15) | (85.74) | (87.44) | (49.37) | (55.51) | (110.77) | (343.49) | (234.30) | +12,706.5 pt | |||||
| ROIC | 0.00 | 0.00 | 0.00 | (193.40) | (169.00) | (235.24) | (191.07) | (468.04) | (1,217.24) | 0.00 | (865.85) | 0.0 pt | ||||||
| ROE | 0.00 | (88.47) | (1,143.73) | (81.57) | (99.72) | (93.45) | (51.97) | (59.63) | (134.52) | (1,625.11) | (705.71) | (1,625.1) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | 2 | 2 | 1 | 3 | 5 | 7 | 6 | 6 | 7 | — | +17.0% | |||||
| Revenue/emp, $m | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fundamentals updated 2 Nov 2026
Artelo Biosciences, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| ELAB PMGC Holdings Inc. | $1.3M | — (loss-making) | — | +147.70% (above 0%: growing) | n/m | −44.95% (below 0%: shrinking) | 29.52% | (292.91%) | Compare |
| LABT Lakewood-Amedex Biotherapeutics Inc. | $1.3M | — (loss-making) | — | — | n/m | −420.66% (below 0%: shrinking) | — | 0.00% | Compare |
| PTIX Atrinsic Inc. | $1.3M | 0.2× | — | +34.31% (above 0%: growing) | n/m | +46.07% (above 0%: growing) | 0.00% | 0.00% | Compare |
| BDRX Biodexa Pharmaceuticals PLC Unsponsored ADR | $1.3M | — (loss-making) | — | −32.27% (below 0%: shrinking) | +96.36% (above 0%: growing) | −0.17% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| ARTL Artelo Biosciences, Inc. | $1.2M | — (loss-making) | — | — | n/m | −879.18% (below 0%: shrinking) | 0.00% | 0.00% | |
| MTNB Matinas Biopharma Holdings, Inc. | $1.1M | — (loss-making) | — (loss-making) | 0.00% | n/m | +9.15% (above 0%: growing) | 0.00% | 0.00% | Compare |
| BBLG Bone Biologics Corp. | $1.1M | — (loss-making) | — | — | n/m | +9.99% (above 0%: growing) | — | 0.00% | Compare |
| VBIO Valion Bio, Inc. | $1.1M | — (loss-making) | — (loss-making) | +15.87% (above 0%: growing) | n/m | −189.01% (below 0%: shrinking) | (99.32%) | 0.00% | Compare |
| BPTH Bio-Path Holdings, Inc. | $1.1M | — (loss-making) | — (loss-making) | — | n/m | +98.68% (above 0%: growing) | 0.00% | 0.00% | Compare |
| Median of peers | $1.2M | — | — | +15.87% | — | +4.49% | 0.00% | 0.00% |
Pay and ownership Proxy statement filed 5 June 2026
Chief executive’s pay
| Year | Total pay | Actually paid | $100 invested |
|---|---|---|---|
| 2025 | 1.21m | 883.19k | 7,070.00 |
| 2024 | 1.06m | 879.83k | 36,680.00 |
| 2023 | 994.10k | 664.63k | 48,440.00 |
Ownership
Directors and executive officers, together
3.20%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards
at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s
shares at the start of the earliest year shown was worth at each year’s end.
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement